PMID- 9789895
OWN - NLM
STAT- MEDLINE
DCOM- 19981229
LR  - 20161021
IS  - 1124-0490 (Print)
IS  - 1124-0490 (Linking)
VI  - 15
IP  - 2
DP  - 1998 Sep
TI  - Measurement of serum monocyte chemoattractant protein-1 and its clinical 
      application for estimating the activity of granuloma formation in sarcoidosis.
PG  - 165-72
AB  - BACKGROUND AND AIM OF THE WORK: The role of monocyte chemoattractant protein-1 
      (MCP-1) in bronchoalveolar lavage fluids from sarcoidosis patients was previously 
      reported. To study the role of MCP-1, we evaluated the serum MCP-1 and its 
      clinical significance in sarcoidosis. METHODS: The serum MCP-1 level was measured 
      in 47 patients with sarcoidosis and 10 normal healthy controls with the use of an 
      enzyme-linked immunosorbent assay. The localization and mRNA expression of MCP-1 
      in sarcoid lymph nodes were evaluated by an immunohistochemical method using an 
      anti-MCP-1 monoclonal antibody and an in situ hybridization technique to 
      determine the cellular source(s) of MCP-1. RESULTS: Serum MCP-1 levels were 
      significantly elevated in the sarcoidosis patients compared with the healthy 
      controls (698.3 +/- 101.9 vs. less than 39 pg/ml, p < 0.001). A comparison of the 
      patients' serum MCP-1 levels among standard radiographic stages revealed that the 
      serum MCP-1 was significantly higher in early stages: stage 0 vs. III, and stage 
      I vs. II. In addition, the serum MCP-1 levels were significantly correlated with 
      the serum angiotensin converting enzyme levels (r = 0.539, p = 0.0006). MCP-1 
      expression was detected in macrophages peripheral to the epithelioid granuloma in 
      sarcoid lymph nodes, by both immunohistochemistry and in situ hybridization. 
      CONCLUSIONS: These data suggest that MCP-1 may be expressed by the macrophages in 
      the granuloma throughout the body, and that the measurement of serum MCP-1 levels 
      may have clinical value as an indicator in estimating the activity of granuloma 
      formation throughout the body in sarcoidosis.
FAU - Iyonaga, K
AU  - Iyonaga K
AD  - First Department of Internal Medicine, Kumamoto University School of Medicine, 
      Japan. iyonaga@kaiju.medic.kumamoto-u.ac.jp
FAU - Suga, M
AU  - Suga M
FAU - Ichiyasu, H
AU  - Ichiyasu H
FAU - Yamamoto, T
AU  - Yamamoto T
FAU - Hiraga, Y
AU  - Hiraga Y
FAU - Ando, M
AU  - Ando M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Italy
TA  - Sarcoidosis Vasc Diffuse Lung Dis
JT  - Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG
JID - 9610928
RN  - 0 (Chemokine CCL2)
RN  - 0 (RNA, Messenger)
RN  - EC 3.4.15.1 (Peptidyl-Dipeptidase A)
SB  - IM
CIN - Sarcoidosis Vasc Diffuse Lung Dis. 1998 Sep;15(2):131-3. PMID: 9789889
MH  - Adult
MH  - Aged
MH  - Bronchoalveolar Lavage Fluid/cytology
MH  - Cell Count
MH  - Chemokine CCL2/*blood/genetics
MH  - Disease Progression
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Granuloma, Respiratory Tract/*blood/diagnosis/physiopathology
MH  - Humans
MH  - In Situ Hybridization
MH  - Lymph Nodes/metabolism/pathology
MH  - Macrophages, Alveolar/metabolism/pathology
MH  - Male
MH  - Middle Aged
MH  - Peptidyl-Dipeptidase A/blood
MH  - RNA, Messenger/biosynthesis
MH  - Respiratory Function Tests
MH  - Sarcoidosis, Pulmonary/*blood/diagnosis/physiopathology
EDAT- 1998/10/28 00:00
MHDA- 1998/10/28 00:01
CRDT- 1998/10/28 00:00
PHST- 1998/10/28 00:00 [pubmed]
PHST- 1998/10/28 00:01 [medline]
PHST- 1998/10/28 00:00 [entrez]
PST - ppublish
SO  - Sarcoidosis Vasc Diffuse Lung Dis. 1998 Sep;15(2):165-72.